[Interpretation of the 2021 American Academy of Allergy, Asthma and Immunology expert consensus on the treatment of postinfectious olfactory dysfunction]

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023 Feb;37(2):81-86. doi: 10.13201/j.issn.2096-7993.2023.02.001.
[Article in Chinese]

Abstract
in English, Chinese

Respiratory tract viruses are the second leading cause of olfactory dysfunction. Between 2019 to 2022, the world has been plagued by the problem of olfaction caused by the COVID-19. As we learn more about the impact of severe acute respiratory syndrome coronavirus 2（SARS-CoV-2）, with the recognition that olfactory dysfunction is a key symptom of this disease process, there is a greater need than ever for evidence-based management of postinfectious olfactory dysfunction（PIOD）. The Clinical Olfactory Working Group has proposed theconsensus on the roles of PIOD. This paper is the detailed interpretation of the consensus.

摘要: 呼吸道病毒是临床上引起嗅觉功能障碍的第二大常见原因。2019-2022年间，全球一直经历着新冠疫情的困扰，疫情引发的嗅觉问题逐渐受到专家们的关注。随着我们对严重急性呼吸系统综合征冠状病毒（SARS-CoV-2）引发症状的了解不断深入，发现嗅觉障碍是该疾病进展中的重要一环，因而对于基于循证医学的病毒感染后失嗅（PIOD）的治疗方法是目前所亟需的。临床嗅觉工作组为此发表了一篇针对PIOD的治疗共识。本文特对该专家共识进行了解读。.

Keywords: Corona Virus Disease 2019; guideline; olfactory disorders; viral infections.

Publication types

  • English Abstract

MeSH terms

  • Asthma* / complications
  • COVID-19* / complications
  • Consensus
  • Humans
  • Hypersensitivity* / complications
  • Olfaction Disorders* / etiology
  • Olfaction Disorders* / therapy
  • SARS-CoV-2
  • Smell
  • United States

Grants and funding

国家自然科学基金项目(No：81800887)